Ionis Pharmaceuticals, Inc.

NasdaqGS IONS

Ionis Pharmaceuticals, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -36.49%

Ionis Pharmaceuticals, Inc. EBIT Margin is -36.49% for the Trailing 12 Months (TTM) ending September 30, 2024, a 28.62% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Ionis Pharmaceuticals, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -51.12%, a -2,356.09% change year over year.
Ionis Pharmaceuticals, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 2.27%, a 105.70% change year over year.
Ionis Pharmaceuticals, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -39.74%, a -367.30% change year over year.
Ionis Pharmaceuticals, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 14.87%, a -20.25% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqGS: IONS

Ionis Pharmaceuticals, Inc.

CEO	Dr. Brett P. Monia Ph.D.
IPO Date	May 17, 1991
Location	United States
Headquarters	2855 Gazelle Court
Employees	927
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Key trends

Past 5 years